18106-1-AP

antibody from Proteintech Group

Targeting: PDCD1 CD279, hSLE1, PD-1, PD1, SLEB2

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

18106-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#18106-1-AP, RRID:AB_10732952

Product name

PD-1/CD279 antibody

Antibody type

Polyclonal

Description

PD-1/CD279 antibody (Cat. #18106-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IF, IHC, ELISA.

Reactivity

Human, Mouse

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Methylation and Expression of the Exercise-Related TLR1 Gene Is Associated With Low Grade Glioma Prognosis and Outcome.

Lu L, Hu Y, Wang C, Jiang F, Wu C
Frontiers in molecular biosciences 2021;8:747933

---

Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.

Sasaki K, Nishina S, Yamauchi A, Fukuda K, Hara Y, Yamamura M, Egashira K, Hino K
Cellular and molecular gastroenterology and hepatology 2021;11(3):739-762

---

TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma.

Bao S, Jiang X, Jin S, Tu P, Lu J
Frontiers in oncology 2021;11:694145

---

Clinical significance of sarcoid-like reaction in lymph nodes of gastric cancer patients.

Itai Y, Ueda Y, Etoh T, Shirasaka Y, Shiroshita H, Shiraishi N, Daa T, Inomata M
Journal of surgical oncology 2021 Sep;124(3):293-300

---

Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.

Xu HZ, Li TF, Wang C, Ma Y, Liu Y, Zheng MY, Liu ZJ, Chen JB, Li K, Sun SK, Komatsu N, Xu YH, Zhao L, Chen X
Journal of nanobiotechnology 2021 Sep 6;19(1):268

---

Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.

Deng Y, Su W, Zhu J, Ji H, Zhou X, Geng J, Zhu J, Zhang Q
Journal for immunotherapy of cancer 2021 Oct;9(10)

---

Involvement of PD-L1-mediated Tumor Intrinsic Signaling and Immune Suppression in Tumorigenic Effect of α-Tocopherol.

Sun Z, Yin S, Zhao C, Fan LH, Hu H
Carcinogenesis 2021 Oct 17;

---

The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator.

Zhou L, Wen L, Sheng Y, Lu J, Hu R, Wang X, Lu Z, Yang Q
Archives of dermatological research 2021 Nov;313(9):751-758

---

Altered peripheral helper T cells in peripheral blood and muscle tissue of the patients with dermatomyositis.

Hou X, Yang C, Lin M, Tian B, Zhao S, Liu X, Yang P
Clinical and experimental medicine 2021 Nov;21(4):655-661

---

PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.

Wu L, Cai S, Deng Y, Zhang Z, Zhou X, Su Y, Xu D
International immunopharmacology 2021 May;94:107443

---

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.

Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu YD, Guo RP
Cancer cell international 2021 Jul 12;21(1):371

---

Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.

Guo CH, Hsia S, Chung CH, Lin YC, Shih MY, Chen PC, Peng CL, Henning SM, Hsu GW, Li Z
The Journal of nutritional biochemistry 2021 Jan;87:108504

---

Antifibrotic effect of Gancao Ganjiang decoction is mediated by PD-1 / TGF-β1 / IL-17A pathway in bleomycin-induced idiopathic pulmonary fibrosis.

Wang D, Gong L, Li Z, Chen H, Xu M, Rong R, Zhang Y, Zhu Q
Journal of ethnopharmacology 2021 Dec 5;281:114522

---

Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer.

Zanker DJ, Spurling AJ, Brockwell NK, Owen KL, Zakhour JM, Robinson T, Duivenvoorden HM, Hertzog PJ, Mullins SR, Wilkinson RW, Parker BS
Clinical & translational immunology 2020;9(9):e1177

---

BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.

Li X, Xu Z, Cui G, Yu L, Zhang X
OncoTargets and therapy 2020;13:215-224

---

Synergistic anti-liver cancer effects of curcumin and total ginsenosides.

Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, Wang ZQ, Tian XF
World journal of gastrointestinal oncology 2020 Oct 15;12(10):1091-1103

---

Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions.

Yu L, Feng R, Zhu L, Hao Q, Chu J, Gu Y, Luo Y, Zhang Z, Chen G, Chen H
Science advances 2020 Nov;6(47)

---

New insight on the correlation of metabolic status on ¹⁸F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.

Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X
European journal of nuclear medicine and molecular imaging 2020 May;47(5):1127-1136

---

Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.

Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, Liu PY
International journal of molecular sciences 2020 Mar 31;21(7)

---

Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.

Wu F, Li GZ, Liu HJ, Zhao Z, Chai RC, Liu YQ, Jiang HY, Zhai Y, Feng YM, Li RP, Zhang W
The Journal of pathology 2020 Jul;251(3):272-283

---

Programmed cell death protein 1 promotes hepatitis B virus transmission through the regulation of ERK1/2-mediated trophoblasts differentiation.

Yang J, Liu J, Sheng M, Zhang X, Liu M
Archives of gynecology and obstetrics 2020 Feb;301(2):551-558

---

Efficient Gene Silencing by Adenine Base Editor-Mediated Start Codon Mutation.

Wang X, Liu Z, Li G, Dang L, Huang S, He L, Ma Y, Li C, Liu M, Yang G, Huang X, Zhou F, Ma X
Molecular therapy : the journal of the American Society of Gene Therapy 2020 Feb 5;28(2):431-440

---

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS
NPJ precision oncology 2019;3:21

---

Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.

Zhou L, Liu D, Xie Y, Yao X, Li Y
Gut and liver 2019 Mar 15;13(4):430-439

---

Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.

Gao M, Lin M, Moffitt RA, Salazar MA, Park J, Vacirca J, Huang C, Shroyer KR, Choi M, Georgakis GV, Sasson AR, Talamini MA, Kim J
British journal of cancer 2019 Jan;120(1):88-96

---

Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.

Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, Li YD, Bei JX, Chen WK, Zhang Q
The International journal of biological markers 2019 Dec;34(4):398-405

---

Estradiol Attenuates the Severity of Primary Toxoplasma gondii Infection-Induced Adverse Pregnancy Outcomes Through the Regulation of Tregs in a Dose-Dependent Manner.

Qiu J, Zhang R, Xie Y, Wang L, Ge K, Chen H, Liu X, Wu J, Wang Y
Frontiers in immunology 2018;9:1102

---

PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.

Yang F, Zeng Z, Li J, Zheng Y, Wei F, Ren X
Frontiers in oncology 2018;8:604

---

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma.

Tang Y, He Y, Shi L, Yang L, Wang J, Lian Y, Fan C, Zhang P, Guo C, Zhang S, Gong Z, Li X, Xiong F, Li X, Li Y, Li G, Xiong W, Zeng Z
Oncotarget 2017 Jun 13;8(24):39001-39011

---

Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.

Jiang L, Zhao Z, Jiang S, Lin Y, Yang H, Xie Z, Lin Y, Long H
Immunologic research 2015 Jul;62(3):316-24

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

HEK-293 cells were subjected to SDS PAGE followed by western blot with 18106-1-AP(PD-1 antibody) at dilution of 1:500

Sample type

cell line

Immunohistochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human lymphoma using 18106-1-AP(PD-1 antibody) at dilution of 1:50 (under 10x lens)

Sample type

tissue

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human lymphoma using 18106-1-AP(PD-1 antibody) at dilution of 1:50 (under 40x lens)

Sample type

tissue

Flow cytometry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

The PD-1/CD279 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human PD-1/CD279. This antibody recognizes human antigen. The PD-1/CD279 antibody has been validated for the following applications: ELISA, WB, IHC, FC analysis.

Appendix

18106-1-AP.pdf

Show more